Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 0.79 |
| ▸ | MTNR1B | P49286 | 16/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | APEX1 | P27695 | 1/20 | 0.67 |
| ▸ | HTR2B | P41595 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | THPO | P40225 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342256 | 0.89 | MTNR1A (0.82) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1773582 | 0.89 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| Sulfuric Acid SCHEMBL2468595 | 0.84 | MTNR1A (0.91) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8041780 | 0.81 | MTNR1A (0.83) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29575897 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL674970 | 0.81 | MTNR1A (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9189819 | 0.81 | MTNR1A (0.91) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31543696 | 0.81 | MTNR1A (0.91) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8053222 | 0.80 | MTNR1A (0.81) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1772618 | 0.80 | HTR2B (1.00) | MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260086089-A1 | DEVICE, METHOD AND SYSTEM FOR DIAGNOSING, MONITORING AND PREDICTING CHRONIC HEALTH CONDITIONS THROUGH URINE BIOMARKERS | HERSTASIS HEALTH FOUND (CA) | 2026-03-26 | — | — | US | claimed |
| US-20250369953-A1 | METHODS FOR MEASURING CIRCADIAN RHYTHM FACTORS | RAIEWSKI EVAN (US) | 2025-12-04 | — | — | US | claimed |
| US-20250251395-A1 | MOLECULES FOR DETECTION OF BIOMARKERS IN BODILY EMISSIONS | OUTSENSE DIAGNOSTICS LTD. (IL) | 2025-08-07 | — | — | US | claimed |
| EP-4591063-A1 | DEVICE, METHOD AND SYSTEM FOR DIAGNOSING, MONITORING AND PREDICTING CHRONIC HEALTH CONDITIONS THROUGH URINE BIOMARKERS | Herstasis Health Foundation (CA) | 2025-07-30 | — | — | EP | claimed |
| WO-2024059934-A1 | DEVICE, METHOD AND SYSTEM FOR DIAGNOSING, MONITORING AND PREDICTING CHRONIC HEALTH CONDITIONS THROUGH URINE BIOMARKERS | HERSTASIS HEALTH FOUNDATION (CA) | 2024-03-28 | — | — | WO | claimed |
| EP-3620794-A1 | DETERMINING A CIRCADIAN RHYTHM | Vanda Pharmaceuticals Inc. (US) | 2020-03-11 | — | — | EP | claimed |
| US-10555919-B2 | Melatonin in autoimmune disease | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2020-02-11 | — | — | US | claimed |
| US-20170333371-A1 | MELATONIN IN AUTOIMMUNE DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-11-23 | — | — | US | claimed |
| EP-3217973-A1 | MELATONIN IN AUTOIMMUNE DISEASE | The Brigham and Women's Hospital, Inc. (US) | 2017-09-20 | — | — | EP | claimed |
| WO-2016077654-A1 | MELATONIN IN AUTOIMMUNE DISEASE | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-05-19 | — | — | WO | claimed |
| US-20160008325-A1 | ISCHEMIA/REPERFUSION PROTECTION COMPOSITIONS AND METHODS OF USING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-14 | — | — | US | claimed |
| US-20120295287-A1 | PREPARING HAPTEN-SPECIFIC ANTIBODIES AND THEIR APPLICATION FOR IMMUNODIAGNOSTICS AND RESEARCH | PHARMASAN LABS, INC. (US) | 2012-11-22 | — | — | US | claimed |
| WO-2011057200-A1 | PREPARING HAPTEN-SPECIFIC ANTIBODIES AND THEIR APPLICATION FOR IMMUNODIAGNOSTICS AND RESEARCH | PHARMASAN LABS, INC. (US) | 2011-05-12 | — | — | WO | claimed |
| WO-1996029315-A2 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-09-26 | — | — | WO | claimed |
| US-5500225-A | MONITORING MELATONIN LEVELS AND ADMINISTERING TO COMPENSATE FOR DEFICIENCIES | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 1996-03-19 | — | — | US | claimed |
| EP-4749285-A1 | DETECTION OF BIOMARKERS IN BIOLOGICAL SAMPLES | Outsense Diagnostics Ltd. (IL) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026104861-A1 | IODBR1 AND DERIVATIVES THEREOF FOR TREATING SLEEP DISORDERS | PHYTOQUEST LIMITED (GB) | 2026-05-21 | — | — | WO | disclosed |
| US-5500225-A | MONITORING MELATONIN LEVELS AND ADMINISTERING TO COMPENSATE FOR DEFICIENCIES | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 1996-03-19 | — | — | US | disclosed |
| US-5500225-A | MONITORING MELATONIN LEVELS AND ADMINISTERING TO COMPENSATE FOR DEFICIENCIES | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 1996-03-19 | — | — | US | disclosed |
| WO-1995026713-A1 | HETEROFUNCTIONAL, MUCOADHESIVE DOSAGE FORM | BIOTEC CENTRE S.A. (FR) | 1995-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260086089-A1 | DEVICE, METHOD AND SYSTEM FOR DIAGNOSING, MONITORING AND PREDICTING CHRONIC HEALTH CONDITIONS THROUGH URINE BIOMARKERS | SHBG, TPO, BRCA1 | MTNR1A 283/4885MTNR1B 133/4885CYP1A2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.